{
    "clinical_study": {
        "@rank": "55504", 
        "acronym": "SUSTAIN\u2122 4", 
        "arm_group": [
            {
                "arm_group_label": "Semaglutide 0.5 mg/week", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Semaglutide 1.0 mg/week", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Insulin glargine", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Africa, North and South America, Asia and Europe. The purpose of\n      the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide\n      versus insulin glargine once-daily on glycaemic control after 30 weeks of treatment in\n      insulin-na\u00efve subjects with type 2 diabetes."
        }, 
        "brief_title": "Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-na\u00efve Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, 18 years or older at the time of signing informed consent\n\n          -  Insulin-na\u00efve subjects diagnosed with type 2 diabetes and on stable diabetes\n             treatment with metformin or metformin and SU (metformin 1500 mg or higher or maximum\n             tolerated dose and SU half of maximum allowed dose according to national label or\n             higher) for at least 90 days before screening. Stable is defined as unchanged\n             medication and unchanged dose\n\n          -  HbA1c 7.0 - 10.0% (53 - 86 mmol/mol) both inclusive\n\n        Exclusion Criteria:\n\n          -  Female who is pregnant, breast-feeding or intends to become pregnant or of\n             childbearing potential not using adequate contraceptive method (adequate\n             contraceptive measures as required by local regulation or practice) throughout the\n             trial including the 5 week follow-up period\n\n          -  Any disorder which, in the opinion of the Investigator might jeopardise subject's\n             safety or compliance with the protocol\n\n          -  Treatment with any glucose lowering agent(s) other than stated in the inclusion\n             criteria in a period of 90 days before screening. An exception is short-term\n             treatment (7 days or less in total) with insulin in connection with intercurrent\n             illness\n\n          -  History of chronic or idiopathic acute pancreatitis\n\n          -  Screening calcitonin value greater than or equal to 50 ng/L\n\n          -  Personal or family history of medullary thyroid carcinoma or multiple endocrine\n             neoplasia syndrome 2\n\n          -  Severe renal impairment defined as estimated glomerular filtration rate (eGFR) less\n             than 30 mL/min/1.73 m^2 per modification of diet in renal disease (MDRD) formula (4\n             variable version)\n\n          -  Acute coronary or cerebrovascular event within 90 days before randomisation\n\n          -  Heart failure, New York Heart Association Class IV\n\n          -  Known proliferative retinopathy or maculopathy requiring acute treatment according to\n             the opinion of the investigator\n\n          -  Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin\n             cancer or squamous cell skin cancer)\n\n          -  Mental inability, unwillingness or language barrier precluding adequate understanding\n             of or compliance with study procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1047", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02128932", 
            "org_study_id": "NN9535-3625", 
            "secondary_id": [
                "2013-004392-12", 
                "U1111-1146-0211"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Semaglutide 0.5 mg/week", 
                "description": "Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.", 
                "intervention_name": "semaglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Semaglutide 1.0 mg/week", 
                "description": "Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly and 4 doses (4 weeks) of 0.5 mg semaglutide subjects will receive 1.0 mg semaglutide weekly for 22 weeks.", 
                "intervention_name": "semaglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin glargine", 
                "description": "Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.", 
                "intervention_name": "insulin glargine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Metformin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 29, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aguascalientes", 
                        "country": "Mexico", 
                        "zip": "20230"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ljubljana", 
                        "country": "Slovenia", 
                        "zip": "1525"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Mexico", 
                "Slovenia"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-na\u00efve Subjects With Type 2 Diabetes", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Croatia: Ministry of Health and Social Care", 
                "France: Ministry of Health", 
                "Germany: Paul-Ehrlich-Institut", 
                "India: Ministry of Health", 
                "Macedonia, The Former Yugoslav Republic of: Ministry of Health", 
                "Mexico: National Institute of Public Health, Health Secretariat", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Slovakia: State Institute for Drug Control", 
                "Slovenia: Agency for Medicinal Products - Ministry of Health", 
                "South Africa: Medicines Control Council", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in HbA1c from baseline", 
            "safety_issue": "No", 
            "time_frame": "Week 0, week 30"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02128932"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in body weight from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 30"
            }, 
            {
                "measure": "Change in fasting plasma glucose from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 30"
            }, 
            {
                "measure": "Change in systolic and diastolic blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 30"
            }, 
            {
                "measure": "Change in patient reported outcome (PRO) questionnaire SF-36v2\u2122 from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 30"
            }, 
            {
                "measure": "Change in patient reported outcome (PRO) questionnaire DTSQs (diabetes treatment satisfaction questionnaire) from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 30"
            }, 
            {
                "measure": "Subjects who achieve HbA1c equal to or below 6.5% (48 mmol/mol) American Association of Clinical Endocrinologists (AACE) target: (yes/no)", 
                "safety_issue": "No", 
                "time_frame": "After 30 weeks treatment"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}